DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?

An article comparing Doximity (DOCS) and iRhythm Technologies (IRTC) highlights their contrasting positions in the AI-driven digital health market; DOCS reported FY25 revenues of $570.4M, a 20% increase, but its stock dipped due to conservative FY26 guidance, while IRTC, specializing in AI-driven cardiac monitoring, saw its stock surge 61.4% YTD after raising its FY25 revenue outlook to $690-$700M following strong growth and clinical validation of its Zio platform. While DOCS offers stability and profitability, IRTC presents a higher-risk, higher-reward profile driven by innovation in diagnostics and margin improvements.

Analysis

Doximity (DOCS) and iRhythm Technologies (IRTC) present distinct investment profiles within the AI-powered digital health sector. Doximity, a clinician-centered platform, reported robust fiscal 2025 results with revenues growing 20% year-over-year to $570.4 million and free cash flow increasing by 56%. In its fourth quarter of fiscal 2025, DOCS generated $138.3 million in revenue and $62.5 million in net income, underscoring its profitability. However, its stock performance has been modest, up 6.9% year-to-date, partly due to conservative fiscal 2026 revenue guidance of $619 million to $631 million, which fell below analyst expectations, and risks associated with drug-pricing reforms and pharmaceutical advertising budgets. In contrast, iRhythm Technologies, specializing in AI-driven cardiac monitoring, has demonstrated strong momentum. IRTC's full-year 2024 revenues rose 20.1% to $591.8 million, and first-quarter 2025 revenues increased 20.3% to $158.7 million. IRTC's stock has surged 61.4% year-to-date, fueled by an improved gross margin (68.8% in Q1 2025), a strong cash position of $520.6 million, and a raised full-year 2025 revenue outlook to $690-$700 million. Although IRTC is not yet profitable, posting a Q1 2025 net loss of $30.7 million, this figure is improving. Both companies are leveraging AI: Doximity through tools like Doximity GPT for clinical workflows, experiencing a fivefold increase in AI tool adoption in FY25, while iRhythm's Zio platform, supported by its ZEUS AI, received significant clinical validation from the AVALON study. Doximity offers stability and existing profitability, whereas iRhythm presents a higher-growth, higher-risk profile focused on diagnostic innovation. Both stocks carry a Zacks Rank #3 (Hold); however, the article notes DOCS has a Zacks Style Score of 'D', which it states reflects better growth prospects compared to IRTC’s score of 'F'.

Key Decisions for Investors

• Investors seeking stability and current profitability in the digital health AI space might consider Doximity, while being mindful of its conservative guidance and exposure to pharmaceutical advertising shifts.
• For those with a higher risk appetite targeting significant growth, iRhythm Technologies offers exposure to AI-driven diagnostic innovation and strong revenue momentum, though its path to profitability should be closely monitored.
• Evaluate Doximity's extensive user base and consistent cash flow against iRhythm's disruptive technology and market expansion potential, aligning investment choices with individual risk tolerance and long-term growth expectations.
• Monitor upcoming earnings reports and product development milestones for both companies, particularly IRTC's progress on margin improvement and DOCS's ability to navigate evolving pharmaceutical market dynamics.